Companies
Acquired by KnowBe4
Acquired by Apple
Acquired by Capital D
Acquired by Oracle
Acquired by Siemens
Acquired by ERT Inc
IPO: AREC
IPO: ORTX
IPO: FRLN
IPO: ACHL
IPO: MGTX
Acquired by Facebook
IPO: BKNG
Acquired by Anthropic
Explore our investments
-
Life Sciences investments
-
Investing since2016In collaboration with UCL Business
-
Total investment£2bnOver $2bn of follow on funding for our companies
-
Public offerings4 IPOsFour Nasdaq IPOs
Featured investments
Breakthrough gene therapy transforms teenager's life | The Times
Breakthrough gene therapy transforms teenager’s life
AlbionVC: London still outpaces Paris in tech | UKTN
Ed Lascelles, AlbionVC Partner shares insights on the State of European Tech: Why London Still Leads
Universities should not be greedy with technology spin-offs | FT
Dave Grimm, Partner at AlbionVC, chats to John Gapper, Financial Times, on the opportunities that commercialising research presents, on the back of our very successful partnership with UCL.
Companies
-
Achilles TherapeuticsBiopharmaceutical company developing precision T cell therapies
Life SciencesIPO -
Apollo Therapeuticsbiopharmaceutical company advancing a robust pipeline of potentially transformative therapeutic programs Life SciencesGrowth
-
Axovia TherapeuticsGene therapy company developing disease-transformative medicines for ciliopathies Life SciencesEarly Stage
-
Bloomsbury GTXBiotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases Life SciencesExited
-
EpilepsyGTxBiotechnology company developing of cutting-edge gene therapies to treat focal refractory epilepsy Life SciencesEarly Stage
-
EpsilogenImmuno-oncology company targeting cancer with the IgE class of antibodies Life SciencesEarly Stage
-
FreelineBiopharmaceutical company focused on the development of liver-directed gene therapies Life SciencesIPO
-
Meira GTXVertically integrated, clinical stage gene therapy company Life SciencesIPO
-
NovalGenImmuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer Life SciencesEarly Stage
-
Orchard TherapeuticsBiotechnology company bringing transformative gene therapies to patients with serious and life-threatening orphan diseases Life SciencesIPO
-
Panangium TherapeuticsBiologic for retinal disease targeting a novel alternative pathway to VEGF Life SciencesEarly Stage
-
Quell TherapeuticsA clinical stage company transforming lives in immune mediated disease Life SciencesGrowth
